Pipeline

One critical path.
Three targets.
Three potential treatments.

At Yaqrit we are developing end-to-end solutions for patients with advanced liver disease, built around a deep and new understanding of the role of inflammation and the body’s response to liver injury in the pathogenesis of the syndrome.

Dysbiosis and leaky gut

Inflammation leads to a cycle of liver cell death

Loss of liver function leads to further aggravation of liver & other organ(s) failing

Organ Failure

Carbalive

Target 1

Removes endotoxin, reduces bacterial translocation and improves organ function

TLR4 antagonist

Target 2

Reduces sensitivity to endotoxin, modulating inflammation

Dialive

Target 3

Removes endotoxin in the blood and replaces damaged albumin, modulating inflammation

References

1.

Toll-like receptor 4, a protein in humans that is encoded by the TLR4 gene.

2.

Damage Associated Molecular Patterns.

3.

Macnaughtan J. (2014). Modulation of the gut-liver axis in cirrhosis with activated carbon. Available at: https://discovery.ucl.ac.uk/id/eprint/1547585/1/PhDThesisMacnaughtanFINAL040417.pdf

Clinical Development Pipeline

Advancing a clinical stage pipeline designed to address each stage of liver disease from diagnosis of decompensated cirrhosis in a hospital setting, to critically ill patients in intensive care.

Target 1

Removes endotoxin, reduces bacterial translocation and improves organ function

Phase

Phase 21

Discovery
Preclinical
Phase 1
Phase 2
Phase 3

Decompensated cirrhosis

NASH 2

PSC 3

Target 2

Reduces sensitivity to endotoxin, modulating inflammation

Phase

Phase 2

Discovery
Preclinical
Phase 1
Phase 2
Phase 3

Treatment of ACLF

Prevention of ACLF

Hyperammonaemia

Urea cycle enzyme disorders

Target 3

Removes endotoxin in the blood and replaces damaged albumin modulating inflammation

Phase

Phase 21

Discovery
Preclinical
Phase 1
Phase 2
Phase 3

Treatment of Severe ACLF

References

1.

Phase 2 equivalent – Randomised controlled clinical trials in patients are usually called Phase 2 trials in the pharmaceuticals industry. Carbalive and Dialive are following a medical device regulatory pathway in Europe, and ‘Phase 2 equivalent’ indicates that have completed randomised controlled clinical trials

2.

NASH – Nonalcoholic steatohepatitis

3.

PSC – Primary Sclerosing Cholangitis